

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/3364Z_1-2023-5-14.pdf

Commercial International Bank (Egypt) S.A.E.

Condensed Sep

Condensed Separate Interim Statement of Financial Position as at March 31,

	<i>Notes</i>	Mar. 31, 2023 EGP Thousands	Dec. 31, 202 EGP Thousands
Assets			
Cash and balances at the central bank	<i>8</i>	52,319,656	47,384,57
Due from banks	<i>9</i>	169,608,129	133,766,19
Loans and advances to banks, net	<i>11</i>	616,088	2,978,19
Loans and advances to customers, net	<i>12</i>	212,026,712	192,621,28
Derivative financial instruments		2,087,218	1,939,96
Investments			
Financial Assets at Fair Value through OCI -	<i>13</i>	184,988,891	202,916,22
Financial Assets at Amortized cost -	<i>13</i>	43,228,737	34,178,75
Investments in associates and subsidiaries -	<i>14</i>	2,116,344	1,074,25
Noncurrent assets held for sale	<i>27</i>	159,828	
Other assets	<i>15</i>	14,686,237	14,454,86
Deferred tax assets		-	24,24
Property and equipment	<i>16</i>	2,357,699	2,304,51
Total assets		<u>684,195,539</u>	<u>633,643,06</u>
Liabilities and equity			
Liabilities			
Due to banks	<i>17</i>	8,286,858	3,475,84
Due to customers	<i>18</i>	574,113,802	530,124,90
Derivative financial instruments		8,294	219,75
Deferred tax liabilities		303,511	
Current income tax liabilities		1,991,935	3,051,58
Other liabilities	<i>19</i>	16,012,509	11,549,47
Issued debt instruments	<i>20</i>	3,069,231	2,456,60
Other loans		9,586,379	7,978,97
Other provisions	<i>21</i>	8,699,209	7,065,29
Total liabilities		<u>622,071,728</u>	<u>565,922,43</u>
Equity			
Issued and paid up capital		29,990,563	29,825,13
Reserves		24,012,537	19,502,71
(Reserve for employee stock ownership plan (ESOP		1,667,377	1,895,43
* Retained earnings		<u>6,453,334</u>	<u>16,497,34</u>
Total equity and net profit for the period / year		<u>62,123,811</u>	<u>67,720,63</u>
Total liabilities and equity		<u>684,195,539</u>	<u>633,643,06</u>

*The accompanying notes are an integral part of these financial
statements
(Limited review report attached)
Including net profit for the current period*

Hussein Abaza
CEO & Managing Director

Chairman

Hisham Ezz

	<i>Notes</i>	Mar. 31, 2023 EGP Thousands	Mar. 31, 2022 EGP Thousands
Interest and similar income		19,729,848	11,812,196
Interest and similar expense		<u>(8,897,778)</u>	<u>(5,209,537)</u>
Net interest income		<u>10,832,070</u>	<u>6,602,659</u>
Fee and commission income		2,004,350	1,191,476
Fee and commission expense		<u>(792,102)</u>	<u>(514,635)</u>
Net fee and commission income		<u>1,212,248</u>	<u>676,841</u>
Dividend income		32,362	37,800
Net trading income	<i>5</i>	1,845,604	716,066
Profits (Losses) on financial investments	<i>13</i>	70,920	1,021,334
Administrative expenses		(2,004,617)	(1,545,348)
Other operating (expenses) income	<i>6</i>	(1,969,625)	(1,425,498)
Impairment release (charges) for credit losses		<u>(947,656)</u>	<u>40,525</u>
Profit before income tax		9,071,306	6,124,379
Income tax expense	<i>25</i>	(2,264,671)	(1,375,213)
Deferred tax assets ((Liabilities)	<i>25</i>	<u>(722,182)</u>	<u>(509,574)</u>
Net profit for the period		<u>6,084,453</u>	<u>4,239,592</u>
Earning per share	<i>7</i>		
Basic		1.81	1.26
Diluted		1.79	1.24

Hussein Abaza
CEO & Managing
Director

Hisham Ezz El-Arab
Chairman

Condensed Separate Interim Statement of Comprehensive Income for the period ended March 31 2023

	Mar. 31, 2023 EGP Thousands	Mar. 31, 2022 EGP Thousands
Net profit for the period	6,084,453	4,239,592
Change in fair value of Financial investments measured at fair value through comprehensive income after tax	(8,507,038)	(3,958,945)
Transferred to RE from financial assets at fair value through comprehensive income	(1,895)	(4,201)
Effect of ECL in fair value of debt instruments measured at fair value through comprehensive income	<u>208,250</u>	<u>101,561</u>
Total comprehensive income for the period	<u>(2,216,230)</u>	<u>378,007</u>

Condensed Separate Cash flows for the period ended March 31 2023

	Notes	Mar. 31, 2023 EGP Thousands
Cash flow from operating activities		
Profit before income tax		9,071,306
Adjustments to reconcile profits to net cash provided by operating activities		
Fixed assets depreciation	16	206,400
Impairment (Released) charge for credit losses (Loans and advances to customers and banks)		714,714
Other provisions charges	21	464,368
(Impairment (Released) charge for credit losses (due from banks		(1,549)
(Impairment (Released) charge for credit losses (financial investments		234,491
Impairment (Released) charge for other assets		-
Exchange revaluation differences for financial assets at fair value through OCI and AC		(6,033,831)
Utilization of other provisions	21	(345)
Other provisions no longer used	21	-
Exchange differences of other provisions	21	1,169,894
profits from selling property and equipment		(118)
profits from selling financial investments at fair value through OCI	13	(70,920)
Share-based payments		100,074

	SHARES BASED PAYMENTS	120,214
Operating profits before changes in operating assets and liabilities		<u>5,945,384</u>
Net decrease (increase) in assets and liabilities		
Due from banks		12,102,385
Financial assets at fair value through P&L		-
Derivative financial instruments		(358,715)
Loans and advances to banks and customers	12 - 11	(17,757,613)
Other assets		(75,936)
Due to banks	17	4,811,010
Due to customers	18	43,988,897
Current income tax obligations paid		(272,736)
Other liabilities		<u>(362,831)</u>
Net cash generated from (used in) operating activities		<u>48,019,845</u>
Cash flow from investing activities		
Payments for investment in subsidiaries		(1,216,022)
Payment for purchases of property, equipment and branches constructions		(415,435)
Proceeds from selling property and equipment		118
Proceeds from redemption of financial assets at amortized cost		196,783
Payment for purchases of financial assets at amortized cost		(8,454,232)
Payment for purchases of financial assets at fair value through OCI		(32,426,908)
Proceeds from selling financial assets at fair value through OCI		<u>46,782,676</u>
Net cash generated from (used in) investing activities		<u>4,466,980</u>

Condensed Separate Interim Cash flows for the period ended March 31, 2023 (Cont.)

	Mar. 31, 2023 EGP Thousands	Mar. 31, 2022 EGP Thousands
Cash flow from financing activities		
Other loans	1,607,404	1,607,404
Dividends paid	(1,964,603)	(4,466,980)
Issued debt instruments	612,624	
Capital increase	<u>165,429</u>	
Net cash generated from (used in) financing activities	<u>420,854</u>	<u>(2,759,576)</u>
Net (decrease) increase in cash and cash equivalent during the period	52,907,679	53,907,679
Beginning balance of cash and cash equivalent	<u>92,895,143</u>	<u>60,000,000</u>
Cash and cash equivalent at the end of the period	<u>145,802,822</u>	<u>114,000,000</u>
:Cash and cash equivalent comprise		
Cash and balances at the central bank	52,319,656	30,000,000
Due from banks	169,655,814	120,000,000
Treasury bills and other governmental notes	68,681,151	40,000,000
Obligatory reserve balance with CBE	(45,888,981)	(26,000,000)
Due from banks with maturities more than three months	(29,664,721)	(10,000,000)
Treasury bills with maturity more than three months	<u>(69,300,097)</u>	<u>(40,000,000)</u>
Total cash and cash equivalent	<u>145,802,822</u>	<u>114,000,000</u>

Net profit of the period	-	-	-	-	-	-	-	6,0
Transferred to RE from financial assets at fair value through OCI	-	-	-	-	-	(1,895)	-	1,8
Net unrealized gain/(loss) on financial assets at fair value through OCI after tax	-	-	-	-	-	(8,507,038)	-	-
Transferred (from) to banking risk reserve	-	-	-	-	-	-	3,249	(3,
Effect of ECL in fair value of debt instruments measured at fair value through OCI	-	-	-	-	-	208,250	-	-
Cost of employees stock (ownership plan (ESOP	-	-	-	-	-	-	-	-
Ending balance of the period	<u>29,990,563</u>	<u>4,770,354</u>	<u>39,095,497</u>	<u>1,549,445</u>	<u>21,155</u>	<u>(21,439,144)</u>	<u>15,230</u>	<u>6</u>



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

QRFAIMFTMTIBBFJ